Optimizing lymphoDepletion to Improve Outcomes In Patients Receiving Cell Therapy With Yescarta

NCT05950802 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

DLBCL - Diffuse Large B Cell Lymphoma

Interventions

DRUG: Cyclophosphamide
RADIATION: TLI

Sponsor

University Health Network, Toronto